retatrutide weight loss trial results ๐ may be redefining obesity treatment. New data from TRIUMPH-1 showed: ๐ฅ ~28% average over 80 weeks ๐ฅ >30% weight loss in nearly half of participant #ObesityMedicine #Retatrutide #GLP1 #CardioMetabolic Antigua - Eli Lilly's experimental
Description
The core GLP-1 consumers, so far, are overwhelmingly young, urban and affluent, and they see these drugs as a major priority and luxury
This month, were highlighting coverage of the FDAs recent warning to telehealth companies regarding the marketing of compounded GLP-1 drugs
Since CPP is a behavioral marker of a substances hedonic value, these results indicate that GLP-1RAs may attenuate the affective component of reinforcement, i.e., liking
NICE guidance emphasises individualised care, and treatment decisions should be made collaboratively between patients and healthcare professionals, considering the overall benefit-risk profile for each individual
GLP-1 agonists help your body make more of the hormone GLP-1 (glucagon-like peptide 1)
